Evaxion A/S

Stage 1 · Basing · week 3

As of Oct 22, 2026, Evaxion is in Stage 1, the basing phase, now in week 3 (since Oct 2, 2026). It closed at $3.71, 44.0% below its 52-week high and above its 200-day average, which is falling.

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. More about the company

$3.71

+0.00% today

$33.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is EVAX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S4 22w

S4 31w

S1 15w

S2 15w

S4 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 14w → S1 3w → S4 22w → S1 6w → S4 11w → S1 4w → S4 2w → S1 1w → S4 31w → S1 15w → S2 15w → S3 9w → S4 7w → S1 8w → S4 15w → S1 3w current

Total tracked: 166 weeks across 16 stage runs.

EVAX among Biotechnology336th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…336	EVAXEvaxion A/S	Stage 1 · wk 3	26	+13.1%

vs 52W High

-44.0%

$2.76 lo$6.63 hi

44.0% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 3

1w13w26w

Week 3, early base

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

4.2%

200 DMA: $3.56 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.38x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

→

Short-term trend flat

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+13.1%

+25.3%

-12.7%

YTD

-21.2%

-43.2%

Scan Membership

Breakout Watch

Latest: 2022-11-29

2 appearances in last 60 days. First seen: 2021-11-18.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 3 · Vol 0.38x

2026-10-21S1

Wk 3 · Vol 1.16x

2026-10-20S1

Wk 3 · Vol 1.98x

2026-10-19S1

Wk 3 · Vol 1.81x

2026-10-16S1

Wk 3 · Vol 0.29x

2026-10-15S1

Wk 2 · Vol 0.14x

2026-10-14S1

Wk 2 · Vol 0.20x

2026-10-13S1

Wk 2 · Vol 0.53x

2026-10-12S1

Wk 2 · Vol 0.24x

2026-10-09S1

Wk 2 · Vol 0.11x

2026-10-08S1

Wk 1 · Vol 0.25x

2026-10-07S1

Wk 1 · Vol 0.09x

Moving averages & range

50 DMA

$3.19

200 DMA

$3.56

52W High

$6.63

52W Low

$2.76

5D Low

$2.83

Resistance levels (recent highs)

20d High

$4.05

60d High

$4.05

120d High

$4.57

250d High

$6.63

Next resistance

+9.2%

to 20d High

ROE

-109.9%

Profit margin -115.5%

Dividend Yield

0.00%

P/B 3.2

Evaxion: quick answers

What stage is Evaxion in?

As of Oct 22, 2026, Evaxion (EVAX) is in Stage 1, the basing phase. It entered Stage 1 on Oct 2, 2026 and is in week 3. What the four stages mean

Is Evaxion in an uptrend?

Not yet. Evaxion is in Stage 1, a base that can come before an uptrend. It trades 4.2% above its 200-day average, which is falling.

How far is Evaxion from its 52-week high?

Evaxion closed at $3.71 on Oct 22, 2026, 44.0% below its 52-week high of $6.63. Its 52-week low is $2.76.

How has Evaxion performed over the past year?

As of Oct 22, 2026, Evaxion is down 43.2% over the past year and down 21.2% so far in 2026.

Which sector and industry is Evaxion in?

Evaxion is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.